Rukobia FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
Rukobia (fostemsavir) is a first-in-class, human immunodeficiency virus type 1 (HIV-1) gp120-directed attachment inhibitor indicated for use in combination with other antiretroviral(s) for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.
Development timeline for Rukobia
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.